8-K: Sagimet Biosciences Reports Positive Phase 2b Results and Prepares for Phase 3 Trials

Sagimet Biosciences announced positive results from its Phase 2b FASCINATE-2 trial for denifanstat in MASH and is preparing to initiate a Phase 3 program in the second half of 2024.

Summary

• Sagimet Biosciences reported its second quarter 2024 financial results and provided corporate updates, highlighting the positive 52-week data from the Phase 2b FASCINATE-2 clinical trial of denifanstat for MASH.
• The trial showed statistically significant improvements in liver fibrosis and a delay in progression to cirrhosis.
• Denifanstat is a fatty acid synthase (FASN) inhibitor that targets the key drivers of MASH: fat accumulation, inflammation, and fibrosis.
• The company plans to initiate a Phase 3 clinical development program for denifanstat in MASH in the second half of 2024.
• Sagimet's cash, cash equivalents, and marketable securities totaled $188.5 million as of June 30, 2024, which is expected to fund operations through 2025.
• Research and development expenses for the quarter were $6.3 million, and general and administrative expenses were $4.3 million.
• The net loss for the quarter was $8.1 million.
• Two new members, Anne Phillips and Jennifer Jarrett, joined the Board of Directors on August 1, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a strong financial position, indicating a high likelihood of success for the company. The sentiment is very positive due to the strong efficacy data and the clear path to Phase 3 trials.

Positives

• Denifanstat demonstrated statistically significant improvements in liver fibrosis and delayed progression to cirrhosis in MASH patients.
• The drug showed enhanced treatment effects in patients using GLP-1 therapies.
• Denifanstat is the only fat synthesis inhibitor that directly targets the three key drivers of MASH.
• The company has a strong cash position of $188.5 million, expected to fund operations through 2025.
• The company is progressing towards initiating a Phase 3 program for denifanstat in MASH.
• The company has a strategic collaboration with Ascletis for acne and cancer indications.
• The company has a strong IP portfolio with patents extending to 2032 and 2036, with potential for extensions.

Negatives

• The company reported a net loss of $8.1 million for the three months ended June 30, 2024.
• Research and development expenses increased to $6.3 million for the quarter compared to $4.7 million in the same period last year.
• General and administrative expenses also increased to $4.3 million for the quarter compared to $2.4 million in the same period last year.
• Some patients experienced hair thinning as an adverse event, though this was generally manageable with dose adjustments.

Risks

• The company's future success depends on the successful completion of Phase 3 clinical trials for denifanstat.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The company's relationship with Ascletis and the success of their development efforts for denifanstat are critical.
• The company's estimates regarding capital requirements may not be accurate.
• The company's ability to maintain and enforce adequate intellectual property protection is crucial.
• There are risks associated with the clinical development and therapeutic potential of denifanstat or any other drug candidates the company may develop.

Future Outlook

The company anticipates initiating a Phase 3 program for denifanstat in MASH in the second half of 2024 and expects its current cash reserves to fund operations through 2025. The Phase 3 study of denifanstat in acne is expected to be fully enrolled by the end of 2024.

Management Comments

• David Happel, Chief Executive Officer of Sagimet, stated that the encouraging data from the FASCINATE-2 trial demonstrate denifanstat's mechanism of action as the only fat synthesis inhibitor that directly targets the three key drivers of MASH.
• David Happel also mentioned that the company plans to initiate the Phase 3 program for denifanstat in MASH in the second half of 2024 and intends to share the Phase 3 pivotal trial design later in the year.

Industry Context

The announcement is significant as MASH is a growing global health concern with limited treatment options. Sagimet's denifanstat, with its unique mechanism of action, is positioned to potentially address a significant unmet need in the treatment of MASH. The positive results from the Phase 2b trial and the planned Phase 3 program are important steps in the development of a new treatment for this disease.

Comparison to Industry Standards

• The results of the FASCINATE-2 trial are promising when compared to other MASH treatments in development.
• While some other companies are developing drugs that target inflammation or fibrosis, denifanstat is unique in that it targets all three key drivers of MASH: fat accumulation, inflammation, and fibrosis.
• For example, Madrigal Pharmaceuticals' resmetirom, a thyroid hormone receptor-beta agonist, has shown positive results in reducing liver fat and fibrosis, but it does not directly target fat synthesis like denifanstat.
• Intercept Pharmaceuticals' obeticholic acid (OCA) has been approved for primary biliary cholangitis and has shown some efficacy in NASH, but it has not demonstrated the same level of fibrosis improvement as denifanstat in the FASCINATE-2 trial.
• The statistically significant improvements in fibrosis and the delay in progression to cirrhosis observed with denifanstat are competitive with the results of other late-stage MASH drug candidates.
• The fact that denifanstat showed enhanced treatment effects in patients using GLP-1 therapies is also a positive differentiator, as GLP-1 therapies are commonly used in patients with metabolic disorders.

Management Changes

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the company's progress towards Phase 3 trials.
• Employees may feel more secure about the company's future due to the positive developments and strong financial position.
• Patients with MASH may have increased hope for a new and effective treatment option.
• The company's collaboration with Ascletis may benefit both companies and their stakeholders.

Next Steps

• The company plans to initiate a Phase 3 clinical development program for denifanstat in MASH in the second half of 2024.
• The company intends to share the Phase 3 pivotal trial design later in the year.
• The Phase 3 study of denifanstat in acne, conducted by Ascletis Pharmaceuticals, is expected to be fully enrolled by the end of 2024.
• The company will continue the development of tripalmitin and additional markers as potential biomarker(s) of treatment response for denifanstat.
• The company will continue preclinical combination studies with other MASH, diabetes, metabolism and obesity molecules.
• The company plans a Phase 2 trial in pediatric MASH following compilation of safety data and a nonclinical toxicology study in juvenile animals.

Key Dates

Keywords

MASH, denifanstat, FASN inhibitor, liver fibrosis, clinical trial, Phase 3, biopharmaceutical, metabolic dysfunction, Ascletis, acne, cancer